ICBs that target programmed cell death1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or ICB plus TKIs are now standard treatment options for RCC [4,5]. This evidence concerns the gene CD274 and renal cell carcinoma.